Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 341

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1A
Chunk 341
---
,765 (16,366)Inventories15,806 6,110 (17,858)Prepaid expenses and other assets(19,352)(334)12,303 Accrued product returns and rebates14,431 2,609 18,941 Accounts payable and other liabilities(15,015)(36,287)(19,163)Payment of contingent consideration— — (2,100)Net cash provided by operating activities171,951 111,085 116,826 Cash flows from investing activitiesPurchases of marketable securities(688,013)(101,621)(406,990)Maturities of marketable securities498,871 370,901 190,739 Purchases of property and equipment(725)(551)(412)Net cash provided by (used in) investing activities(189,867)268,729 (216,663)Cash flows from financing activitiesProceeds from Credit Line— 93,000 — Payments on Credit Line— (93,000)— Payment on convertible notes— (402,500)— Proceeds from issuance of common stock14,908 6,610 12,423 Employee taxes paid related to net share settlement of equity awards(2,715)(1,990)— Payment of contingent consideration— — (22,900)Net cash provided by (used in) financing activities12,193 (397,880)(10,477)Net change in cash and cash equivalents(5,723)(18,066)(110,314)Cash and cash equivalents at beginning of year75,054 93,120 203,434 Cash and cash equivalents at end of year$69,331 $75,054 $93,120 Supplemental cash flow informationCash paid for income taxes$53,254 $36,602 $16,200 Cash paid for interest on debt$— $1,946 $2,516 Noncash investing and financing activitiesProperty and equipment additions from utilization of tenant improvement allowance— — $580 

See accompanying notes.

96

Table of ContentsSupernus Pharmaceuticals, Inc.Notes to Consolidated Financial Statements

1. Business Organization

Supernus Pharmaceuticals, Inc. (the Company, see Consolidation in Note 2, Summary of Significant Accounting Policies) was incorporated in Delaware and commenced operations in 2005. The Company is a bioph